Envoy Medical (COCH) Q2 2024 earnings summary

Executive summary

• Advanced toward pivotal clinical trial for fully implanted Acclaim cochlear implant, aiming for IDE submission and potential enrollment by year-end 2024.

• Early Feasibility Study at Mayo Clinic showed all participants using the device daily with improved quality-of-life scores after 18 months.

• System noise issues addressed with technical updates, improving signal-to-noise ratio and programming optimization.

• Flexibility of Acclaim implant allows use of hearing aids or consumer electronics in the implanted ear, offering a potential differentiator.

Financial highlights

• Q2 2024 revenue was $68,000, up from $63,000 in Q2 2023, driven by two Esteem FI-AMEI unit sales despite lower battery sales.

• Cost of goods sold increased by $83,000 year-over-year due to manufacturing scrap, contractor costs, and expanded manufacturing space.

• R&D expenses rose by $438,000 to $2.6 million, reflecting increased headcount and preparation for clinical trials.

• Sales and marketing expenses increased by $114,000 to $497,000, mainly due to higher market access fees.

• General and administrative expenses decreased by $250,000 to $1.6 million, primarily from lower professional and legal fees.

• Net loss for Q2 2024 was $3.95 million, compared to $13.25 million in Q2 2023.

• Cash and cash equivalents stood at $1.7 million as of June 30, 2024.

Outlook and guidance

• Targeting IDE submission for pivotal clinical trial in the coming months, with potential enrollment before year-end 2024.

• Commercialization of the Acclaim cochlear implant may be achievable by end of 2026, pending regulatory approvals.